The impact of comorbid type 2 diabetes on survival outcomes in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis focusing on lung cancer

1

Patients with type 2 diabetes mellitus (T2DM) show poorer overall survival (OS) and progression-free survival (PFS) when treated with immune checkpoint inhibitors (ICIs).
2

The meta-analysis included six studies with 1,225 participants, revealing a hazard ratio of 1.49 for OS and 1.38 for PFS in T2DM patients receiving ICIs.
3

Subgroup analyses indicated consistently poorer OS in T2DM patients regardless of sample size or type of survival analysis conducted.
4

No significant difference in PFS was found between T2DM and non-T2DM patients treated with ICIs when sample sizes exceeded 200 or in multivariate analyses.
5

The study concludes that while T2DM may negatively impact OS in lung cancer patients treated with ICIs, further research is needed to confirm these findings.

1